Charles River Laboratories and Sanofi have partnered to explore the use of Virtual Control Groups (VCGs) in nonclinical toxicology. VCGs can reduce animal usage by replacing selected control animals with matched virtual counterparts based on historical data.
This initiative aligns with Charles River’s Alternative Methods Advancement Project (AMAP), aiming to reduce animal use in research. By combining toxicological science with machine learning, Charles River can drive VCG adoption in the industry.
VCGs are data-driven creations that rely on historical study parameters and statistical methods. They are an established practice in clinical trials but are new to preclinical research. Charles River and Sanofi are collaborating to pilot VCGs in toxicology programs.
Philippe Detilleux, Global Head of Preclinical Safety at Sanofi, indicated that VCGs represent a significant opportunity to advance sustainable science by reducing reliance on animal models.
As more studies incorporate VCGs, the resulting data will enhance their refinement and suitability as replacements for research animals. The partnership between Charles River and Sanofi aims to drive industry stakeholders’ adoption of VCGs.
AMAP, led by Charles River, supports the development of alternatives to animal testing through strategic investments. The goal is to invest $300 million over the next five years to drive industry-wide adoption of alternatives that ensure patient safety and treatment efficacy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
